Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Duvelisib Plus Docetaxel in PD-1 Inhibitor Experienced Patients With Incurable Head and Neck Squamous Cell Carcinoma

NCT05057247 is registered in ClinicalTrials.gov with Kartik Sehgal, MD as lead sponsor.

NCT NCT05057247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05057247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Duvelisib Plus Docetaxel in PD-1 Inhibitor Experienced Patients With Incurable Head and Neck Squamous Cell Carcinoma
Lead sponsor
Kartik Sehgal, MD
Phase
Phase 2
Overall status
Completed
Start date
October 14, 2021
Completion date
June 13, 2024
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced head and neck cancer, advanced head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent squamous cell carcinoma of the head and neck, squamous cell carcinoma of the head and neck (scchn)